Covid & Vaccine Spike Protein, Persistent Symptoms, and Nattokinase
Introduction
Since the COVID-19 pandemic began, one question has continued to surface in both scientific research and patient discussions: What happens to the synthetic spike protein after it is introduced to the body, or the spike protien that is produced in the body after a covid-19 infection? Whether generated during a COVID-19 infection or through mRNA vaccination, the spike protein has become an important focus as researchers work to understand how the body processes and clears it. Some scientists have also explored whether fragments of spike protein from the virus itself might persist in certain individuals and potentially contribute to lingering symptoms.
In his technical article “Dissolution of Spike Protein by Nattokinase,” cardiologist Dr. Peter A. McCullough reviews laboratory research examining whether the enzyme nattokinase may be capable of degrading SARS-CoV-2 spike protein under controlled conditions.
Because the original article is highly clinical and complex, this piece aims to translate that science into clearer language. We’ll explore how spike protein is produced, what researchers are learning about possible persistence following COVID infection or vaccination, and why enzymes like nattokinase have entered the conversation.
A Thoughtful Exploration Inspired by Dr. Peter A. McCullough
Based on the article discussion from:
Peter A. McCullough, MD, MPH
“Dissolution of Spike Protein by Nattokinase”
https://www.thefocalpoints.com/p/dissolution-of-spike-protein-by-nattokinase
Since the start of the pandemic, one concern has surfaced repeatedly in private conversations, clinical discussions, and independent medical commentary:
What happens to the spike protein after it’s produced in the body — and could it linger?
Dr. Peter A. McCullough addressed this question directly in his article, “Dissolution of Spike Protein by Nattokinase”
In his article, he reviews laboratory data examining nattokinase and its ability to degrade SARS-CoV-2 spike protein. His writing is highly clinical and technical, referencing biochemical mechanisms, enzymatic activity, and published studies in scientific journals. For readers who are comfortable navigating medical terminology, it provides important depth. However, for many people, the language can feel dense and difficult to follow.
That is why this article was created — not to reinterpret his conclusions, but to translate the science into clearer, more understandable language. The goal is to help everyday readers grasp what spike protein is, how synthetic spike protein is produced through mRNA technology, what concerns have been raised about persistence, and why enzymes like nattokinase have entered the conversation.
Understanding How mRNA Vaccines Produce Spike Protein
To understand why this discussion continues, we need to step back and revisit how mRNA vaccines were developed and deployed during the pandemic, and how synthetic spike protein functions in the body.
During the pandemic, mRNA vaccines were authorized under an Emergency Use Authorization (EUA). This pathway allows medical products to be distributed during public health emergencies once sufficient short-term safety and efficacy data are available. The initial clinical trials for the mRNA vaccines involved tens of thousands of participants and demonstrated strong short-term protection against severe disease.
However, as with any newly developed platform technology, long-term multi-year data simply did not exist at the time of widespread distribution. That’s not unusual for emergency authorizations — but it does mean the complete long-term biological behavior of synthetic spike protein production was still being studied as rollout occurred.
Why Vaccine mRNA Was Designed for Stability
The mRNA used in these vaccines is modified to increase stability. Normally, messenger RNA is rapidly broken down by enzymes in the body called ribonucleases. In the vaccine platform, the mRNA includes modified nucleosides that help it resist rapid degradation so that enough spike protein can be produced to trigger an immune response and develop immunity sensitivity for rapid response when the real virus is introduced.
That design choice was intentional and scientifically rational for achieving an immune response. But some clinicians and researchers have raised questions about how long spike protein may be produced in certain tissues and whether fragments might circulate longer than originally anticipated in some individuals.
The spike protein itself was also engineered with proline substitutions — small structural changes designed to stabilize it in a “prefusion” conformation. In simple terms, it was locked into a specific shape that makes it easier for the immune system to recognize.
When Symptoms Persist: The Human Experience
For most individuals, the immune system clears spike protein after antibody production and cellular immunity are established. That is the expected biological outcome.
However, a subset of individuals have reported persistent symptoms following either COVID-19 infection or vaccination. These reported symptoms have included fatigue, exercise intolerance, chest discomfort, palpitations, brain fog, tingling sensations, and inflammatory-type reactions.
Researchers are still investigating mechanisms behind these symptoms. One hypothesis — not yet definitively proven — is that lingering spike protein fragments could contribute to immune activation or inflammatory signaling in certain cases.
Enter Nattokinase: A Proteolytic Enzyme of Interest
This is where nattokinase enters the discussion.
Nattokinase is a proteolytic enzyme derived from fermented soybeans (natto). Proteolytic simply means it breaks down proteins. Historically, nattokinase has been studied for its ability to degrade fibrin — a protein involved in blood clot formation. Because abnormal clotting patterns have been observed in both COVID-19 infection and some post-vaccination cases, nattokinase gained attention for circulatory support.
But interest intensified when laboratory studies examined its interaction with spike protein directly.
Laboratory Evidence: Spike Protein Degradation
In 2022, Tanikawa et al. published a study in the journal Molecules demonstrating that nattokinase degraded SARS-CoV-2 spike protein in vitro. “In vitro” means the experiment was conducted in a laboratory setting using cell preparations, not in living humans.
The researchers showed that spike protein breakdown increased over time and with higher enzyme concentrations. An earlier study by Oba et al. in 2021 showed that natto extract inhibited SARS-CoV-2 infection in cell models.
These findings do not prove that oral nattokinase dissolves spike protein in humans. But they do demonstrate that spike protein is structurally vulnerable to enzymatic degradation.
For clinicians exploring biological plausibility, that matters.
Human Data: Systemic Effects of Nattokinase
Nattokinase is measured in fibrinolytic units (FU), reflecting its clot-dissolving capacity. Human studies, such as Kurosawa et al. (2015), showed that a single oral dose of 2000 FU increased markers of fibrin degradation within hours. This suggests nattokinase can exert systemic effects after ingestion.
If nattokinase reaches circulation and retains proteolytic activity, it raises a logical question: could it potentially assist in breaking down circulating or tissue-embedded spike protein fragments?
That is the hypothesis.
Why Some Clinicians Consider Systemic Enzyme Therapy
Systemic enzyme therapy is typically used with the goal of supporting protein turnover and inflammatory balance throughout tissues when taken on an empty stomach. The theoretical goal is to allow enzymes to enter circulation rather than being used solely for digestion.
For individuals experiencing symptoms they associate with spike protein exposure, enzyme therapy may feel like a proactive option. The reasoning often sounds like this:
If spike protein persistence is contributing to symptoms, and if nattokinase can degrade spike protein in laboratory studies, and if nattokinase has an established supplement safety profile, then supervised use may be worth discussing.
The Limits of Current Evidence
At the same time, it is important to remain measured. While the vaccine rollout occurred under accelerated timelines due to the urgency of the pandemic, clinical trials were conducted prior to authorization. What was not available at the time — and could not have been — was multi-year longitudinal data on synthetic spike protein biology across diverse populations.
That gap is inherent to any newly deployed medical technology during an emergency.
Ongoing pharmacovigilance — meaning long-term safety monitoring — continues today. As data accumulates, our understanding evolves.
Meanwhile, nattokinase is not without considerations. Because it influences clotting pathways, it may increase bleeding risk, especially in individuals on anticoagulant or antiplatelet medications. Medical supervision is essential.
The larger discussion here is not about certainty but about inquiry. Synthetic spike protein production is a novel biological intervention introduced at an unprecedented global scale. While short-term safety and efficacy were demonstrated, the finer details of long-term spike protein dynamics are still being studied.
For those navigating persistent symptoms, exploring biologically plausible support strategies — under guidance — is understandable.
Why Nattokinase Stands Out
Nattokinase stands out because:
- It is a protein-degrading enzyme
• It has demonstrated spike protein degradation in vitro
• It has documented systemic fibrinolytic activity in humans
• It has years of supplement use data
Nattokinase stands out because it is not just another general digestive enzyme. It is a systemic proteolytic enzyme with documented fibrinolytic activity, meaning it can break down fibrin — the structural protein involved in blood clot formation. That alone makes it unique in the enzyme world.
The Role of Complementary Systemic Enzymes
But nattokinase is rarely discussed in isolation.
In many systemic enzyme formulations, nattokinase is paired with other proteolytic enzymes that support complementary pathways in the body. One such enzyme is Seaprose® S, a highly purified protease originally derived from Aspergillus melleus. Seaprose S is known for its protein-cleaving activity and has been studied for its ability to support healthy inflammatory balance and circulatory function.
Unlike digestive enzymes that primarily act on food in the gut, systemic proteases such as Seaprose S are typically used with the intention of supporting protein turnover throughout the body when taken away from meals. The concept is simple: proteins that are no longer needed — including inflammatory debris or excess fibrin — can accumulate, and specialized enzymes help the body process and clear them efficiently.
Nattokinase directly targets fibrin, enzymes like Seaprose S may assist more broadly in breaking down non-living protein fragments and supporting balanced inflammatory signaling.
Proteases such as bromelain (from pineapple) and papain (from papaya) are sometimes included as well. These enzymes are commonly associated with digestive health, but when taken on an empty stomach, they may contribute to systemic protein breakdown and immune modulation.
A Layered Approach to Enzyme Support
The rationale behind combining enzymes is not to exaggerate a single isolated effect, but to create a coordinated approach to circulation, protein metabolism, and inflammatory balance. Nattokinase may serve as the primary fibrin-targeting enzyme, while complementary proteases like Seaprose S support broader protein-clearing processes.
It is this layered enzyme strategy that many integrative practitioners find compelling. Rather than focusing on a single pathway, systemic enzyme combinations are designed to support the body’s natural cleanup systems in a more comprehensive way.
At the center of that discussion, however, nattokinase remains the most studied enzyme when it comes to fibrin degradation and — in laboratory settings — spike protein dissolution.
Science Is Still Evolving
Whether that translates into clinically meaningful spike protein clearance in humans remains under investigation. The science behind it makes enough sense that many integrative doctors feel it deserves an open discussion.
Science rarely moves in straight lines, and it almost never moves overnight. It unfolds in stages — one study leading to another, one question opening the door to the next. The discussion around synthetic spike protein, possible persistence, and enzyme-based approaches is part of that gradual process. Over time, clearer answers may emerge. Whether substantial resources will be committed to thoroughly investigating these questions at a large scale, however, is something that only time will reveal.
A Practical Perspective for Individuals Seeking Answers
In the meantime, some clinicians and individuals take a practical approach. Given that systemic enzymes like nattokinase have documented protein-degrading activity, established use in circulatory support, and a generally favorable safety profile when used appropriately, many view them as a reasonable option to explore. Advocates argue that when a strategy shows biological plausibility, laboratory support, and relatively low risk when monitored properly, it may be worth considering rather than waiting indefinitely for perfect data. As always, informed decision-making and professional guidance remain essential.
References
McCullough, P.A. (2023). Dissolution of Spike Protein by Nattokinase.
https://www.thefocalpoints.com/p/dissolution-of-spike-protein-by-nattokinase
Tanikawa T, Kiba Y, Yu J, et al. (2022). Degradative Effect of Nattokinase on Spike Protein of SARS-CoV-2. Molecules, 27(17):5405.
https://doi.org/10.3390/molecules27175405
Oba M, Rongduo W, Saito A, et al. (2021). Natto extract directly inhibits viral infections including SARS-CoV-2 in vitro. Biochem Biophys Res Commun, 570:21-25.
https://doi.org/10.1016/j.bbrc.2021.07.034
Kurosawa Y, Nirengi S, Homma T, et al. (2015). A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Scientific Reports, 5:11601.
https://doi.org/10.1038/srep11601
0 Comments